TP53 and neoplasm: Aggarwal et al. [21] noted that it is not clear whether genetically engineered mouse models in which tumor formation is driven by a clinically relevant oncogene or loss of a tumor suppressor gene (e.g., Tp53) can be better predictors of cancer drug discovery than experiments with cell cultures and models that involve non-genetically engineered animals.